But a recent Medicare payment change is putting lives at risk.
Earlier this year, CMS changed the End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) (File Code CMS-1830-P), bundling oral-only phosphate-lowering therapies (PLTs) into dialysis facility payments. This shift moves treatment decisions from doctors and patients to payment administrators — replacing individualized care with a rigid, one-size-fits-all system.
The Science Is Clear
Your body depends on a delicate biochemical balance to survive. For people on dialysis, controlling phosphorus isn’t optional — it’s biology.
Restricting access to the most effective PLTs throws this balance into chaos, causing preventable complications and early death.
CMS Can Still Fix This
By removing PLTs from the PPS bundle and restoring them to Medicare Part D, CMS can:
- Return treatment decisions to physicians and patients
- Protect vulnerable communities from harmful disruptions
- Follow the science to ensure fair access to life-saving medications
The deadline is August 29, 2025.
This is our chance to say: Follow the science. Protect patient choice. Restore access.